Fulgent Genetics, Inc. - 8-K Filing
Fulgent Genetics announced updated preliminary data for FID-007 in combination with cetuximab in treating recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) at the ASCO 2026 Annual Meeting. As of April 16, 2026, the trial showed an objective response rate of 61.9%, median progression-free survival of 6.7 months, one-year overall survival of 63.4%, and activity in both HPV-related and unrelated HNSCC cases. (Items: 8.01 Other Events, 9.01 Financial Statements and Exhibits)
Tickers: $FLGT